Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

Stephen Huang, MD
Published: Thursday, Oct 22, 2015



Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Many of the tools have been known to benefit adult patients with thyroid cancer, are now being shown to be very helpful in the pediatric thyroid cancer population as well, says Huang. However, many challenges remain in the treatment of pediatric patients.

Pediatric patients have higher rates of local and distant metastasis, although outcomes are still positive for most children. The long-term implications and survival of pediatric thyroid cancer is also still not fully understood, says Huang. This is because few studies have followed childhood patients into adulthood. More collaboration needs to occur between pediatric and adult thyroid cancer specialists, he says.

<<< View more from the 2015 International Thyroid Congress



Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Many of the tools have been known to benefit adult patients with thyroid cancer, are now being shown to be very helpful in the pediatric thyroid cancer population as well, says Huang. However, many challenges remain in the treatment of pediatric patients.

Pediatric patients have higher rates of local and distant metastasis, although outcomes are still positive for most children. The long-term implications and survival of pediatric thyroid cancer is also still not fully understood, says Huang. This is because few studies have followed childhood patients into adulthood. More collaboration needs to occur between pediatric and adult thyroid cancer specialists, he says.

<<< View more from the 2015 International Thyroid Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x